PDZD11

Across TCGA pan-cancer cohorts, PDZD11 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PDZD11’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PDZD11 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PDZD11 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and CCRCC are the cancer types where PDZD11 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PDZD11 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−0.490	<.001	8	view →
LSCC	Female	All	−0.330	<.001	6	view →
CCRCC	Male	All	−0.280	<.001	6	view →
OV	All	All	−0.395	.023	2	view →
LUAD	Male	All	−0.131	.008	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PDZD11–HNSC

Open the HNSC breakdown →